- Home
- SLP vs ARCT Comparison
SLP vs ARCT Comparison
Compare SLP & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLP
- ARCT
- Stock Information
- Founded
- SLP 1996
- ARCT 2013
- Country
- SLP United States
- ARCT United States
- Employees
- SLP N/A
- ARCT N/A
- Industry
- SLP EDP Services
- ARCT Biotechnology: Pharmaceutical Preparations
- Sector
- SLP Technology
- ARCT Health Care
- Exchange
- SLP Nasdaq
- ARCT Nasdaq
- Market Cap
- SLP 282.4M
- ARCT 320.8M
- IPO Year
- SLP 1997
- ARCT N/A
- Fundamental
- Price
- SLP $15.05
- ARCT $17.32
- Analyst Decision
- SLP Buy
- ARCT Strong Buy
- Analyst Count
- SLP 7
- ARCT 10
- Target Price
- SLP $29.50
- ARCT $50.88
- AVG Volume (30 Days)
- SLP 388.2K
- ARCT 536.4K
- Earning Date
- SLP 10-22-2025
- ARCT 11-06-2025
- Dividend Yield
- SLP N/A
- ARCT N/A
- EPS Growth
- SLP N/A
- ARCT N/A
- EPS
- SLP N/A
- ARCT N/A
- Revenue
- SLP $80,383,000.00
- ARCT $122,122,000.00
- Revenue This Year
- SLP $12.75
- ARCT N/A
- Revenue Next Year
- SLP $3.06
- ARCT $31.09
- P/E Ratio
- SLP N/A
- ARCT N/A
- Revenue Growth
- SLP 20.01
- ARCT N/A
- 52 Week Low
- SLP $12.39
- ARCT $8.04
- 52 Week High
- SLP $37.67
- ARCT $25.88
- Technical
- Relative Strength Index (RSI)
- SLP 58.45
- ARCT 54.49
- Support Level
- SLP $13.78
- ARCT $17.38
- Resistance Level
- SLP $14.46
- ARCT $18.69
- Average True Range (ATR)
- SLP 0.53
- ARCT 1.00
- MACD
- SLP 0.13
- ARCT -0.11
- Stochastic Oscillator
- SLP 99.16
- ARCT 44.23
About SLP Simulations Plus Inc.
Simulations Plus Inc is engaged in the software industry. It includes two segments. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.